Ratings Novonesis A/S

Equities

NSIS B

DK0060336014

Real-time Estimate Cboe Europe Other stock markets 09:31:46 2024-04-25 am EDT			5-day change	1st Jan Change
383.6 ^DKK	-1.11%		+0.76%	+3.91%

Apr. 08	Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	CI
Mar. 26	China to speed up 'new productive forces', vice president says	RE

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 87% by 2026.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
With an expected P/E ratio at 44.01 and 33.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialty Chemicals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NOVONESIS A/S	+3.91%	25.83B		B+
CATHAY BIOTECH INC.	-26.59%	3.25B	-	C+
BORREGAARD ASA	+10.50%	1.73B		C+
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD.	-27.06%	380M	-	-
BIO-ON S.P.A.	-81.65%	216M	-	-
CHEMCON SPECIALITY CHEMICALS LIMITED	-9.88%	116M	-	-
I-TECH AB	-15.22%	51.4M		D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes